Citigroup’s Seres Therapeutics MCRB Stock Holding History

Citigroup’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,745	Closed	-$105K	–	5769
2023 Q4	$105K	Sell	3,745 -2,490	-40%	-$65.4K	﹤0.01%	4185
2023 Q3	$297K	Sell	6,235 -6,925	-53%	-$528K	﹤0.01%	3419
2023 Q2	$1.26M	Buy	13,160 +6,770	+106%	+$737K	﹤0.01%	2653
2023 Q1	$725K	Buy	6,390 +2,915	+84%	+$315K	﹤0.01%	2826
2022 Q4	$389K	Buy	+3,475	New	+$466K	﹤0.01%	3339

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Citigroup's MCRB Position: Q4 2025 in Review

Citigroup sold out of Seres Therapeutics (MCRB) in Q4 2025, closing a stake of 2,621 shares — an estimated $50.4K sold.

Citigroup first reported a position in MCRB in Q3 2015 and held it in 41 quarters. The position peaked at $4.84M in Q2 2021. 36 funds tracked by Wall St. Rank hold MCRB as of Q4 2025.

Citigroup reported no remaining Seres Therapeutics position as of Q4 2025 after selling out during the quarter.
Citigroup sold 2,621 Seres Therapeutics shares in Q4 2025, an estimated $50.4K.
Citigroup first reported a position in Seres Therapeutics in Q3 2015 and held it in 41 quarters.
Citigroup's Seres Therapeutics position peaked at $4.84M in Q2 2021.
36 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.